Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

246
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
246
Global Regulatory Systems01:28

Global Regulatory Systems

623
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
623
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

327
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
327
Errors in Global Positioning System01:26

Errors in Global Positioning System

345
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
345
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

477
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
477
Global Climate Change01:50

Global Climate Change

28.7K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
28.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same author

Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF?

British journal of pharmacology·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 21, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K

Benralizumab: First Global Approval.

A Markham1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 22, 2018
PubMed
Summary
This summary is machine-generated.

Benralizumab (Fasenra™), an anti-interleukin-5 receptor alpha antibody, is now FDA-approved for severe eosinophilic asthma. This biologic targets eosinophils, offering a new treatment for patients with this specific asthma phenotype.

More Related Videos

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes
12:48

Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes

Published on: April 26, 2009

13.5K

Related Experiment Videos

Last Updated: Jan 21, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes
12:48

Measuring Near Plasma Membrane and Global Intracellular Calcium Dynamics in Astrocytes

Published on: April 26, 2009

13.5K

Area of Science:

  • * Immunology and Respiratory Medicine: Focuses on biologic therapies for severe asthma.
  • * Pharmacology: Investigates monoclonal antibodies targeting specific inflammatory pathways.

Background:

  • * Severe asthma is often characterized by eosinophilia, a condition involving elevated eosinophil levels.
  • * Eosinophil depletion has shown therapeutic potential in managing certain asthma and chronic obstructive pulmonary disease (COPD) phenotypes.
  • * Interleukin-5 receptor alpha (IL-5Rα) is a key target for controlling eosinophilic inflammation.

Purpose of the Study:

  • * To summarize the development of benralizumab (Fasenra™) as a treatment for severe eosinophilic asthma.
  • * To highlight the key milestones leading to the US FDA approval of benralizumab.
  • * To provide an overview of benralizumab's mechanism of action as an anti-IL-5Rα monoclonal antibody.

Main Methods:

  • * Review of preclinical and clinical development data for benralizumab.
  • * Analysis of regulatory submission and approval processes.
  • * Summary of benralizumab's efficacy and safety profile in severe eosinophilic asthma.

Main Results:

  • * Benralizumab, a humanized anti-IL-5Rα monoclonal antibody, has been developed by Kyowa Hakko Kirin and AstraZeneca.
  • * The drug targets and depletes eosinophils, addressing a key feature of specific asthma phenotypes.
  • * Benralizumab received US FDA approval as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype.

Conclusions:

  • * Benralizumab represents a significant advancement in the treatment of severe eosinophilic asthma.
  • * The FDA approval validates benralizumab's efficacy in targeting eosinophilic inflammation.
  • * This development offers a new therapeutic option for patients with difficult-to-treat asthma.